[{"data":1,"prerenderedAt":181},["ShallowReactive",2],{"story-206671-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":29,"questions":30,"relatedArticles":55,"body_color":179,"card_color":180},"206671",null,"Pharma M&A Consolidation Signals Healthcare Supply Chain Shifts | Seller Implications","- $2B biotech acquisition reshapes hematology market; impacts medical device sellers, health supplement categories, and patient support product demand through 2028",[],[10,11,12,13,14,15,11,16,17,18,19,20,21,22,23,24,25,20,10,26,27,10,28,10],"https:\u002F\u002Fs.tradingview.com\u002Fstatic\u002Fimages\u002Fillustrations\u002Fnews-story.jpg","https:\u002F\u002Fcdn.zonebourse.com\u002Fstatic\u002Fresize\u002F1200\u002F675\u002F\u002Fimages\u002Freuters\u002F2025-03-13T172638Z_1_LYNXMPEL2C0VY_RTROPTP_3_BUSINESS-FRANCE.JPG","https:\u002F\u002Fstatic.biospace.com\u002Fdims4\u002Fdefault\u002F9db9813\u002F2147483647\u002Fstrip\u002Ftrue\u002Fcrop\u002F2059x1159+0+148\u002Fresize\u002F1000x563!\u002Fquality\u002F90\u002F?url=https%3A%2F%2Fstatic.biospace.com%2F74%2F9e%2F0b4b0115493f9b707521c1eb4c62%2Fistock-892834918.jpg","https:\u002F\u002Fwww.reuters.com\u002Fresizer\u002Fv2\u002FJNMHF3W225OLJE66UEMC5BLQ4M.jpg?auth=96fc74304c11f7c2bcead2e1391f09c6e5a34d297454a71a06690631727a2526&width=1920&quality=80","https:\u002F\u002Fpharmaphorum.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Fx_large\u002Fpublic\u002F2026-06\u002FBMeury_Incyte_CEO_960x540.jpg?itok=X7YMhYgO","https:\u002F\u002Fcdn.thepharmaletter.com\u002Ffiles\u002F2024\u002F06\u002Fdafc3060-21c1-11ef-b9fd-3d6df514ffbd-Incyte.jpg","https:\u002F\u002Fimgproxy.divecdn.com\u002FhKZ6zklbTnVlgc5IWMbD4Yn0u7LgWv7iDuGcxnP5_jg\u002Fg:ce\u002Frs:fill:1200:675:1\u002FZ3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzY2OTU4MDU4LmpwZw==.webp","https:\u002F\u002Fgrafa.com\u002F_next\u002Fimage?url=https%3A%2F%2Fs3.ap-southeast-2.amazonaws.com%2Fassets.hq.grafa.com%2FDeal%207.jpg&w=3840&q=85","https:\u002F\u002Fwww.contractpharma.com\u002Fwp-content\u002Fuploads\u002Fsites\u002F6\u002F2026\u002F06\u002Fincyte-star.jpg","https:\u002F\u002Fwww.geneonline.com\u002Fwp-content\u002Fuploads\u002F%E5%85%AD%E6%9C%88EN_Mobile-450-%C3%97-350-px.jpg","https:\u002F\u002Fbloximages.chicago2.vip.townnews.com\u002Fdelawarebusinessnow.com\u002Fcontent\u002Ftncms\u002Fassets\u002Fv3\u002Feditorial\u002F3\u002F1d\u002F31d1f079-2086-5ecf-bfcb-d56958f26d8c\u002F660efa48968b4.image.jpg","https:\u002F\u002Fcdn.sanity.io\u002Fimages\u002F0vv8moc6\u002Fpharmexec\u002F0bdf67f64b798bbbc3de98ccd7328942d30a69b9-1280x720.png?w=1280&max-h=720&fit=crop&auto=format","https:\u002F\u002Fimg-s-msn-com.akamaized.net\u002Ftenant\u002Famp\u002Fentityid\u002FAA255L5f.img?w=768&h=513&m=6&x=392&y=199&s=58&d=58","https:\u002F\u002Fpubimg.futunn.com\u002F202205090000029640145feb4f1.jpg","https:\u002F\u002Fwww.citybiz.co\u002Fwp-content\u002Fuploads\u002F2022\u002F11\u002FIncyte.jpg","https:\u002F\u002Fblog.tipranks.com\u002Fwp-content\u002Fuploads\u002F2022\u002F09\u002Fshutterstock_1917115745-750x406.jpg","https:\u002F\u002Fendpoints.news\u002Fwp-content\u002Fuploads\u002F2025\u002F09\u002FAdam-Rosenthal.jpg","https:\u002F\u002Fqtxasset.com\u002Fcdn-cgi\u002Fimage\u002Fw=384,h=216,f=auto,fit=crop,g=0.5x0.5\u002Fhttps:\u002F\u002Fqtxasset.com\u002Fquartz\u002Fqcloud5\u002Fmedia\u002Fimage\u002FGettyImages-1511179609.jpg?VersionId=._rw5NJ3iABUltZwmktyYANf6vwrcqkX","https:\u002F\u002Fimages.wsj.net\u002Fim-68134014?width=700&height=467","**Incyte's $2 billion acquisition of Vega Therapeutics** marks a significant pharmaceutical consolidation event with indirect but measurable implications for e-commerce sellers in health, wellness, and medical device categories. The deal—Incyte's largest strategic investment under CEO Bill Meury—centers on VGA039, a late-phase monoclonal antibody for von Willebrand disease (VWD), a rare bleeding disorder affecting 7,000-10,000 severe U.S. patients. With $1.25 billion upfront and up to $750 million in sales milestones, this transaction reflects broader pharma industry trends toward acquiring late-stage assets to offset patent expirations (Incyte's Jakafi faces patent cliff in 2028).\n\n**Market Consolidation Impact on E-Commerce**: This acquisition signals accelerating pharmaceutical M&A activity, which historically correlates with increased demand for complementary health products. As Incyte positions VGA039 as a potential $1 billion+ annual revenue generator by the late 2020s, patient populations managing bleeding disorders will expand significantly. E-commerce sellers in health categories should anticipate increased demand for: (1) **Medical support products** (compression garments, mobility aids for patients with bleeding complications), (2) **Nutritional supplements** (iron supplements, vitamin K products for bleeding disorder management), (3) **Home healthcare equipment** (first-aid kits, medical alert systems), and (4) **Patient education materials** (digital health guides, condition-specific resources).\n\n**Competitive Dynamics & Supply Chain Signals**: The deal directly challenges Takeda's Vonvendi (FDA-approved 2015), which requires twice-weekly intravenous infusions versus VGA039's monthly subcutaneous dosing. This therapeutic shift—demonstrating 81% median bleed reduction in early trials—will reshape patient management protocols through 2028 when Phase 3 trials complete. For sellers, this indicates: (1) declining demand for IV-administration support products as patients transition to subcutaneous delivery, (2) growing opportunity in subcutaneous injection supplies and training materials, and (3) potential expansion of telehealth-adjacent products as less frequent dosing enables remote patient monitoring. The late 2020s commercialization timeline creates a 3-4 year window for sellers to position inventory and marketing strategies around emerging patient needs.\n\n**Strategic Seller Positioning**: Pharmaceutical acquisitions of this scale typically precede aggressive patient recruitment and awareness campaigns, historically driving 25-40% increases in related health product searches on Amazon, eBay, and specialty health platforms. Sellers should monitor: (1) FDA approval timelines (Phase 3 completion targeted 2028), (2) patient advocacy group activity (VWD Foundation, bleeding disorder organizations), and (3) healthcare provider education initiatives. Categories like medical alert systems, patient support apps, and condition-specific supplements typically see 15-30% demand acceleration during new treatment launches. The 3-year development window provides opportunity to establish authority in bleeding disorder-adjacent categories before mainstream commercialization drives category saturation.",[31,34,37,40,43,46,49,52],{"title":32,"answer":33,"author":5,"avatar":5,"time":5},"How does Incyte's $2B acquisition of Vega Therapeutics affect e-commerce sellers?","Incyte's acquisition of Vega Therapeutics for $2 billion signals major pharmaceutical consolidation that indirectly expands e-commerce opportunities in health and medical device categories. The deal centers on VGA039, a new treatment for von Willebrand disease (VWD) targeting 7,000-10,000 severe U.S. patients. As this therapy moves through Phase 3 trials (completion targeted 2028) toward commercialization, sellers should expect increased demand for complementary products: medical support items, nutritional supplements for bleeding disorder management, home healthcare equipment, and patient education materials. Historical pharma launches typically drive 25-40% increases in related health product searches, creating a 3-4 year window for sellers to establish category authority before mainstream adoption.",{"title":35,"answer":36,"author":5,"avatar":5,"time":5},"What product categories benefit most from this biotech acquisition?","Five primary categories stand to benefit from VGA039's development and commercialization: (1) **Subcutaneous injection supplies** (syringes, needles, injection training kits)—VGA039 requires monthly subcutaneous dosing versus competitor Vonvendi's twice-weekly IV infusions; (2) **Nutritional supplements** (iron supplements, vitamin K products, clotting support formulas) for bleeding disorder management; (3) **Medical alert systems and wearables** for patient safety monitoring; (4) **Home healthcare equipment** (first-aid kits, compression garments, mobility aids); and (5) **Digital health and patient education** (condition-specific guides, telehealth integration tools). The shift from IV to subcutaneous administration particularly benefits injection supply sellers, as patient populations transition to less frequent, self-administered dosing by late 2020s.",{"title":38,"answer":39,"author":5,"avatar":5,"time":5},"What are the patent expiration implications for sellers in 2028?","Incyte's acquisition directly addresses its strategic imperative to diversify revenue streams ahead of Jakafi's patent expiration in 2028. Jakafi is a core revenue driver, and its patent cliff creates urgency for new revenue sources—VGA039's late 2020s commercialization timeline aligns perfectly with this transition. For sellers, this signals: (1) **increased pharmaceutical M&A activity** through 2028 as companies acquire late-stage assets to offset patent losses, (2) **market consolidation** that may reshape competitive dynamics in hematology and related health categories, and (3) **accelerated patient recruitment** as companies race to establish market share before patent-related revenue erosion. Sellers should anticipate heightened marketing and awareness campaigns from Incyte and competitors during 2027-2028, driving 25-40% increases in related health product searches and demand.",{"title":41,"answer":42,"author":5,"avatar":5,"time":5},"Which seller segments are best positioned to capitalize on this acquisition?","Three seller segments are optimally positioned: (1) **Medical device and supply sellers** specializing in injection equipment, subcutaneous administration kits, and patient training materials—VGA039's monthly subcutaneous dosing creates direct demand for these products; (2) **Health supplement and nutritional sellers** focused on bleeding disorder management, iron supplementation, and clotting support formulas—patient populations managing VWD require ongoing nutritional support; and (3) **Digital health and patient education sellers** offering telehealth integration, condition-specific guides, and patient support platforms—less frequent dosing enables remote monitoring and digital engagement. Sellers with existing authority in rare disease categories, patient advocacy relationships, or healthcare provider networks can establish competitive advantages by 2025-2026, capturing early adopter demand before mainstream commercialization in late 2020s.",{"title":44,"answer":45,"author":5,"avatar":5,"time":5},"What is the commercial potential of VGA039 and how does it affect market size?","Incyte projects VGA039 could generate $1 billion or more in annual net sales, positioning it as a major growth driver in the hematology portfolio. CEO Meury compared its potential to Roche's Hemlibra in hemophilia A, suggesting aspirations for standard-of-care status in a historically underserved patient population. The $1B+ annual revenue projection indicates significant market expansion: with 7,000-10,000 severe VWD patients eligible for IV prophylaxis in the U.S., successful commercialization could expand the addressable patient population to 20,000-30,000+ globally. This market expansion directly correlates with increased demand for complementary health products, patient support services, and medical supplies. E-commerce sellers in health categories should anticipate 25-40% category growth in bleeding disorder-related products during the 2028-2030 commercialization phase.",{"title":47,"answer":48,"author":5,"avatar":5,"time":5},"How should sellers monitor this acquisition for competitive intelligence?","Sellers should establish monitoring systems for three key signals: (1) **FDA\u002Fregulatory updates**—track Phase 3 trial progress, safety data releases, and FDA approval timelines through FDA.gov and clinical trial databases; (2) **Patient advocacy activity**—monitor VWD Foundation, bleeding disorder organizations, and patient support groups for awareness campaigns and educational initiatives that signal market expansion; and (3) **Healthcare provider education**—watch for hematology conference presentations, clinical guidelines updates, and provider training programs indicating physician adoption. Historically, pharmaceutical launches see 15-30% demand acceleration in related categories during the 12-18 months preceding approval. Setting up Google Alerts for \"VGA039,\" \"von Willebrand disease,\" and \"Incyte hematology\" enables early detection of market signals, allowing sellers to adjust inventory and marketing strategies 6-12 months ahead of mainstream adoption.",{"title":50,"answer":51,"author":5,"avatar":5,"time":5},"When should sellers start positioning inventory for VGA039 market entry?","Sellers should begin strategic positioning immediately through 2025-2026, as Phase 3 trial completion is targeted for 2028 with regulatory approval and commercialization beginning in the late 2020s. This 3-4 year window allows sellers to: (1) establish authority in bleeding disorder-adjacent categories before mainstream adoption, (2) build relationships with patient advocacy groups (VWD Foundation, bleeding disorder organizations), and (3) develop content and product listings optimized for emerging patient searches. Historically, pharmaceutical launches see 15-30% demand acceleration in related categories during the 12-18 months preceding FDA approval. Early positioning in 2025-2026 captures organic search traffic from newly diagnosed patients and healthcare providers researching treatment options.",{"title":53,"answer":54,"author":5,"avatar":5,"time":5},"How does VGA039's dosing advantage over Vonvendi impact seller strategy?","VGA039's monthly subcutaneous dosing versus Vonvendi's twice-weekly intravenous infusions represents a fundamental shift in patient management that reshapes seller opportunities. Early trial data shows 81% median bleed reduction with 75-100% annualized bleeding rate improvement in patients transitioning from IV prophylaxis. This dosing advantage signals: (1) declining demand for IV-administration support products and training materials, (2) growing opportunity in subcutaneous injection supplies and patient training resources, and (3) potential expansion of telehealth-adjacent products as less frequent dosing enables remote monitoring. Sellers currently focused on IV-related medical supplies should begin diversifying into subcutaneous injection categories by 2026-2027 to capture the patient migration as VGA039 gains market share.",[56,61,66,70,74,78,82,86,90,94,98,102,106,110,113,117,121,125,128,132,136,140,144,147,151,155,159,163,167,171,175],{"id":57,"title":58,"source":59,"logo":28,"time":60},1025467,"Incyte to Buy Vega Therapeutics For Up to $2 Billion","https:\u002F\u002Fwww.wsj.com\u002Ftech\u002Fbiotech\u002Fincyte-to-buy-vega-therapeutics-for-up-to-2-billion-229dcbae","13H AGO",{"id":62,"title":63,"source":64,"logo":10,"time":65},1027107,"INCY: Acquisition of a phase III asset in von Willebrand disease targets blockbuster growth post-2029","https:\u002F\u002Fwww.tradingview.com\u002Fnews\u002Furn:summary_document_transcript:quartr.com:3519032:0-incy-acquisition-of-a-phase-iii-asset-in-von-willebrand-disease-targets-blockbuster-growth-post-2029","9H AGO",{"id":67,"title":68,"source":69,"logo":10,"time":65},1027108,"INCY: Acquisition adds a phase III asset with $1B+ sales potential and FDA Breakthrough status","https:\u002F\u002Fwww.tradingview.com\u002Fnews\u002Furn:summary_document_transcript:quartr.com:3519349:0-incy-acquisition-adds-a-phase-iii-asset-with-1b-sales-potential-and-fda-breakthrough-status",{"id":71,"title":72,"source":73,"logo":11,"time":65},1027109,"Incyte Corporation entered into a definitive agreement to acquire to acquire Vega Therapeutics, Inc. from Star Therapeutics, Inc. for $2 billion.","https:\u002F\u002Fwww.marketscreener.com\u002Fnews\u002Fincyte-corporation-entered-into-a-definitive-agreement-to-acquire-to-acquire-vega-therapeutics-inc-ce7f5dd3d988ff24",{"id":75,"title":76,"source":77,"logo":23,"time":65},1027103,"Press Release: Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding Its Hematology Portfolio Into Bleeding Disorders","https:\u002F\u002Fwww.moomoo.com\u002Fhans\u002Fnews\u002Fpost\u002F71197429\u002Fpress-release-incyte-to-acquire-vega-therapeutics-a-wholly-owned",{"id":79,"title":80,"source":81,"logo":17,"time":65},1027104,"Incyte acquires Vega Therapeutics in $1.25 billion deal","https:\u002F\u002Fgrafa.com\u002Fen\u002Fnews\u002Funited-states\u002Fincyte-vega-therapeutics-acquisition",{"id":83,"title":84,"source":85,"logo":26,"time":60},1025469,"Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal","https:\u002F\u002Fendpoints.news\u002Fincyte-to-buy-bleeding-disorder-biotech-vega-therapeutics-in-1-25b-upfront-deal",{"id":87,"title":88,"source":89,"logo":22,"time":65},1027105,"Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary","https:\u002F\u002Fwww.msn.com\u002Fen-us\u002Fmoney\u002Fmarkets\u002Fincyte-strikes-up-to-2-billion-deal-for-star-therapeutics-subsidiary\u002Far-AA25684n?ocid=finance-verthp-feeds",{"id":91,"title":92,"source":93,"logo":5,"time":60},1025468,"Incyte Corp. (INCY) Nears $2 Billion Acquisition of Star Therapeutics","https:\u002F\u002Fwww.gurufocus.com\u002Fnews\u002F8904583\u002Fincyte-corp-incy-nears-2-billion-acquisition-of-star-therapeutics?mobile=true",{"id":95,"title":96,"source":97,"logo":20,"time":65},1027106,"Incyte to buy bleeding disorder drug candidate in deal valued at up to $2 billion","https:\u002F\u002Fwww.delawarebusinessnow.com\u002Fnews\u002Ffeatured\u002Fincyte-to-buy-bleeding-disorder-drug-candidate-in-deal-valued-at-up-to-2-billion\u002Farticle_d581ab53-ee2f-4a77-b80c-824c21f9bcff.html",{"id":99,"title":100,"source":101,"logo":14,"time":65},1027100,"Incyte gobbles up Star's Vega haematology unit in $2bn deal","https:\u002F\u002Fpharmaphorum.com\u002Fnews\u002Fincyte-gobbles-stars-vega-haematology-unit-2bn-deal",{"id":103,"title":104,"source":105,"logo":16,"time":65},1027101,"Incyte to buy blood disorder drug in possibly $2B deal","https:\u002F\u002Fwww.biopharmadive.com\u002Fnews\u002Fincyte-vega-acquisition-star-biotech-deal-blood-disorder-vwd\u002F822238",{"id":107,"title":108,"source":109,"logo":24,"time":65},1027102,"Incyte to Acquire Vega Therapeutics in Up to $2 Billion Hematology Expansion","https:\u002F\u002Fwww.citybiz.co\u002Farticle\u002F856787\u002Fincyte-to-acquire-vega-therapeutics-in-up-to-2-billion-hematology-expansion",{"id":111,"title":88,"source":112,"logo":5,"time":60},1025475,"https:\u002F\u002Fca.finance.yahoo.com\u002Fnews\u002Fincyte-strikes-2-billion-deal-110740959.html",{"id":114,"title":115,"source":116,"logo":27,"time":65},1027092,"Incyte inks $2B deal to add Star unit to late-phase constellation and challenge Takeda","https:\u002F\u002Fwww.fiercebiotech.com\u002Fbiotech\u002Fincyte-inks-2b-deal-add-star-unit-late-phase-constellation-and-challenge-takeda",{"id":118,"title":119,"source":120,"logo":10,"time":65},1027093,"INCY: Acquisition adds a transformative VWD therapy, boosting growth and market expansion","https:\u002F\u002Fwww.tradingview.com\u002Fnews\u002Furn:summary_document_slides:quartr.com:3518176:0-incy-acquisition-adds-a-transformative-vwd-therapy-boosting-growth-and-market-expansion",{"id":122,"title":123,"source":124,"logo":19,"time":65},1027094,"Incyte, Galmed, and Johnson & Johnson Announce Acquisitions Totaling $3 Billion","https:\u002F\u002Fwww.geneonline.com\u002Fincyte-galmed-and-johnson-johnson-announce-acquisitions-totaling-3-billion",{"id":126,"title":88,"source":127,"logo":13,"time":60},1025470,"https:\u002F\u002Fwww.reuters.com\u002Flegal\u002Ftransactional\u002Fincyte-strikes-up-2-billion-deal-star-therapeutics-subsidiary-2026-06-08",{"id":129,"title":130,"source":131,"logo":18,"time":65},1027099,"Incyte Agrees to Acquire Vega Therapeutics for $1.25B","https:\u002F\u002Fwww.contractpharma.com\u002Fbreaking-news\u002Fincyte-agrees-to-acquire-vega-therapeutics-for-1-25b",{"id":133,"title":134,"source":135,"logo":15,"time":65},1027110,"Incyte to acquire Star subsidiary Vega Therapeutics","https:\u002F\u002Fwww.thepharmaletter.com\u002Fbiotech-news\u002Fincyte-to-acquire-star-subsidiary-vega-therapeutics",{"id":137,"title":138,"source":139,"logo":5,"time":65},1027111,"Incyte (INCY) to Acquire Vega Therapeutics for $1.25B","https:\u002F\u002Fwww.gurufocus.com\u002Fnews\u002F8905068\u002Fincyte-incy-to-acquire-vega-therapeutics-for-125b",{"id":141,"title":142,"source":143,"logo":20,"time":65},1027112,"Incyte to buy company in late stages of development of bleeding control drug","https:\u002F\u002Fwww.delawarebusinessnow.com\u002Fnews\u002Ffeatured\u002Fincyte-to-buy-company-in-late-stages-of-development-of-bleeding-control-drug\u002Farticle_d581ab53-ee2f-4a77-b80c-824c21f9bcff.html",{"id":145,"title":88,"source":146,"logo":5,"time":65},1027113,"https:\u002F\u002Ffinance.yahoo.com\u002Fsectors\u002Fhealthcare\u002Farticles\u002Fincyte-strikes-2-billion-deal-110740959.html",{"id":148,"title":149,"source":150,"logo":25,"time":60},1025474,"Incyte to Acquire Vega Therapeutics in $2B Deal","https:\u002F\u002Fwww.tipranks.com\u002Fnews\u002Fcompany-announcements\u002Fincyte-to-acquire-vega-therapeutics-in-2b-deal",{"id":152,"title":153,"source":154,"logo":21,"time":65},1027095,"Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio","https:\u002F\u002Fwww.pharmexec.com\u002Fview\u002Fpharma-roundup-incyte-acquire-vega-therapeutics-galmed-pharmaceuticals-colospan-johnson-johnson",{"id":156,"title":157,"source":158,"logo":5,"time":60},1025473,"Incyte makes Vega deal official, paying $1.25B upfront for bleeding disorder biotech","https:\u002F\u002Ffirstwordpharma.com\u002Fstory\u002F7537018",{"id":160,"title":161,"source":162,"logo":5,"time":65},1027096,"Incyte Corporation (INCY) Announces Acquisition of Vega Therapeu","https:\u002F\u002Fwww.gurufocus.com\u002Fnews\u002F8905453\u002Fincyte-corporation-incy-announces-acquisition-of-vega-therapeutics",{"id":164,"title":165,"source":166,"logo":10,"time":60},1025472,"Incyte to acquire Vega Therapeutics for $1.25B, up to $2.0B with milestones; VGA039 Phase 3 asset","https:\u002F\u002Fwww.tradingview.com\u002Fnews\u002Ftradingview:0fdd8fbc7cf89:0-incyte-to-acquire-vega-therapeutics-for-1-25b-up-to-2-0b-with-milestones-vga039-phase-3-asset",{"id":168,"title":169,"source":170,"logo":11,"time":65},1027097,"Transcript : Incyte Corporation, Vega Therapeutics, Inc. - M&A Call","https:\u002F\u002Fwww.marketscreener.com\u002Fnews\u002Ftranscript-incyte-corporation-vega-therapeutics-inc-m-a-call-ce7f5dd3d88bf524",{"id":172,"title":173,"source":174,"logo":5,"time":60},1025471,"Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders","https:\u002F\u002Fsg.finance.yahoo.com\u002Fnews\u002Fincyte-acquire-vega-therapeutics-wholly-110000584.html",{"id":176,"title":177,"source":178,"logo":12,"time":65},1027098,"Incyte’s stars align as new CEO strikes $2B Vega takeover for blood disorder asset","https:\u002F\u002Fwww.biospace.com\u002Fbusiness\u002Fincytes-stars-align-as-new-ceo-strikes-2b-vega-takeover-for-blood-disorder-asset","#d1b111ff","#d1b1114d",1780983071166]